Literature DB >> 26937754

Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.

Caroline C Billingsley1, David E Cohn, David G Mutch, Erinn M Hade, Paul J Goodfellow.   

Abstract

OBJECTIVE: POLE mutations in high-grade endometrioid endometrial cancer (EEC) have been associated with improved survival. We sought to investigate the prevalence of POLE tumor mutation and its prognostic significance on outcomes and clinical applications in a subanalysis of women with high-grade EEC from a previously described cohort of 544 EEC patients in which POLE mutation status and survival outcomes were assessed.
METHODS: Polymerase chain reaction amplification and Sanger sequencing were used to test for POLE mutations in 72 tumors. Associations between POLE mutation, demographic and clinicopathologic features, and survival were investigated with Cox proportional hazard models.
RESULTS: POLE mutations were identified in 7 (9.7%) of 72 grade 3 EECs. No significant differences in the clinicopathologic features between those with POLE mutations and those without were identified. Adjusted for age, a decreased risk of recurrence was suggested in patients with a POLE mutation (adjusted hazard ratio, 0.37; 95% confidence interval, 0.09-1.55), as well as decreased risk of death (adjusted hazard ratio, 0.19; 95% confidence interval, 0.03-1.42).
CONCLUSIONS: POLE mutations in tumors of women with grade 3 EEC are associated with a lower risk of recurrence and death, although not statistically significant because of high variability in these estimates. These findings, consistent with recently published combined analyses, support POLE mutation status as a noteworthy prognostic marker and may favor a change in the treatment of women with grade 3 EECs, particularly in those with early-stage disease, in which omission of adjuvant therapy and decreased surveillance could possibly be appropriate.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26937754      PMCID: PMC4874836          DOI: 10.1097/IGC.0000000000000681

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  29 in total

1.  The 3'-->5' exonucleases of both DNA polymerases delta and epsilon participate in correcting errors of DNA replication in Saccharomyces cerevisiae.

Authors:  A Morrison; A Sugino
Journal:  Mol Gen Genet       Date:  1994-02

2.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.

Authors:  C L Creutzberg; W L van Putten; P C Koper; M L Lybeert; J J Jobsen; C C Wárlám-Rodenhuis; K A De Winter; L C Lutgens; A C van den Bergh; E van de Steen-Banasik; H Beerman; M van Lent
Journal:  Lancet       Date:  2000-04-22       Impact factor: 79.321

3.  High incidence of epithelial cancers in mice deficient for DNA polymerase delta proofreading.

Authors:  Robert E Goldsby; Laura E Hays; Xin Chen; Elise A Olmsted; William B Slayton; Gerry J Spangrude; Bradley D Preston
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

4.  Eukaryotic DNA polymerase amino acid sequence required for 3'----5' exonuclease activity.

Authors:  A Morrison; J B Bell; T A Kunkel; A Sugino
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

5.  Yeast DNA polymerase epsilon participates in leading-strand DNA replication.

Authors:  Zachary F Pursell; Isabelle Isoz; Else-Britt Lundström; Erik Johansson; Thomas A Kunkel
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

6.  Hypermutability and mismatch repair deficiency in RER+ tumor cells.

Authors:  R Parsons; G M Li; M J Longley; W H Fang; N Papadopoulos; J Jen; A de la Chapelle; K W Kinzler; B Vogelstein; P Modrich
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

7.  Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.

Authors:  Israel Zighelboim; Paul J Goodfellow; Feng Gao; Randall K Gibb; Matthew A Powell; Janet S Rader; David G Mutch
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

8.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.

Authors:  Henry M Keys; James A Roberts; Virginia L Brunetto; Richard J Zaino; Nick M Spirtos; Jeffrey D Bloss; Andrew Pearlman; Mitchell A Maiman; Jeffrey G Bell
Journal:  Gynecol Oncol       Date:  2004-03       Impact factor: 5.482

9.  POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.

Authors:  Tjalling Bosse; David N Church; Inge C van Gool; Florine A Eggink; Luke Freeman-Mills; Ellen Stelloo; Emanuele Marchi; Marco de Bruyn; Claire Palles; Remi A Nout; Cor D de Kroon; Elisabeth M Osse; Paul Klenerman; Carien L Creutzberg; Ian Pm Tomlinson; Vincent Thbm Smit; Hans W Nijman
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

10.  The 3' to 5' exonuclease activity located in the DNA polymerase delta subunit of Saccharomyces cerevisiae is required for accurate replication.

Authors:  M Simon; L Giot; G Faye
Journal:  EMBO J       Date:  1991-08       Impact factor: 11.598

View more
  16 in total

1.  The genetic landscape of endometrial clear cell carcinomas.

Authors:  Deborah F DeLair; Kathleen A Burke; Pier Selenica; Raymond S Lim; Sasinya N Scott; Sumit Middha; Abhinita S Mohanty; Donavan T Cheng; Michael F Berger; Robert A Soslow; Britta Weigelt
Journal:  J Pathol       Date:  2017-09-05       Impact factor: 7.996

2.  Primum non nocere: Are we ready for POLE testing in endometrial cancer?

Authors:  Casey M Cosgrove; David E Cohn; Paul J Goodfellow
Journal:  Gynecol Oncol       Date:  2017-09-22       Impact factor: 5.482

3.  DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.

Authors:  Min Yuen Teo; Richard M Bambury; Emily C Zabor; Emmet Jordan; Hikmat Al-Ahmadie; Mariel E Boyd; Nancy Bouvier; Stephanie A Mullane; Eugene K Cha; Nitin Roper; Irina Ostrovnaya; David M Hyman; Bernard H Bochner; Maria E Arcila; David B Solit; Michael F Berger; Dean F Bajorin; Joaquim Bellmunt; Gopakumar Iyer; Jonathan E Rosenberg
Journal:  Clin Cancer Res       Date:  2017-01-30       Impact factor: 12.531

4.  Prognostic significance of solid growth in endometrioid endometrial adenocarcinoma.

Authors:  Serra Akar; Zeliha Esin Çelik; Sıddıka Fındık; Tolgay Tuyan İlhan; Fedi Ercan; Çetin Çelik
Journal:  Int J Clin Oncol       Date:  2019-08-26       Impact factor: 3.402

Review 5.  Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy.

Authors:  Stephanie R Barbari; Polina V Shcherbakova
Journal:  DNA Repair (Amst)       Date:  2017-06-09

6.  Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.

Authors:  Marina Stasenko; Irina Tunnage; Charles W Ashley; Maria M Rubinstein; Alicia J Latham; Arnaud Da Cruz Paula; Jennifer J Mueller; Mario M Leitao; Claire F Friedman; Vicky Makker; Robert A Soslow; Deborah F DeLair; David M Hyman; Dimitriy Zamarin; Kaled M Alektiar; Carol A Aghajanian; Nadeem R Abu-Rustum; Britta Weigelt; Karen A Cadoo
Journal:  Gynecol Oncol       Date:  2019-11-19       Impact factor: 5.482

Review 7.  Tailored Therapy Based on Molecular Characteristics in Endometrial Cancer.

Authors:  Suk-Young Lee
Journal:  Biomed Res Int       Date:  2021-05-05       Impact factor: 3.411

8.  Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.

Authors:  Florine A Eggink; Inge C Van Gool; Alexandra Leary; Pamela M Pollock; Emma J Crosbie; Linda Mileshkin; Ekaterina S Jordanova; Julien Adam; Luke Freeman-Mills; David N Church; Carien L Creutzberg; Marco De Bruyn; Hans W Nijman; Tjalling Bosse
Journal:  Oncoimmunology       Date:  2016-12-09       Impact factor: 8.110

9.  Phenotype of POLE-mutated endometrial cancer.

Authors:  Sara Imboden; Denis Nastic; Mehran Ghaderi; Filippa Rydberg; Tilman T Rau; Michael D Mueller; Elisabeth Epstein; Joseph W Carlson
Journal:  PLoS One       Date:  2019-03-27       Impact factor: 3.240

10.  Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations.

Authors:  Niamh Conlon; Arnaud Da Cruz Paula; Charles W Ashley; Sheila Segura; Louise De Brot; Edaise M da Silva; Robert A Soslow; Britta Weigelt; Deborah F DeLair
Journal:  Am J Surg Pathol       Date:  2020-05       Impact factor: 6.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.